Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC)

Rudge, Scott R.; Peterson, Caryn; Vessely, Christina; Koda, Joy E.; Stevens, Sam M.; Catterall, L.G

doi:10.1016/s0168-3659(01)00344-3

Cited by 130 publications

(71 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous experiments using magnetic approach to drug targeting have been performed by some groups with magnetic particles or magnetic liposomes ranging from 10 m to 100 nm, loaded with chemotherapeutic agents (Alexiou et al, 2000;Rudge et al, 2001). Some positive effects were obtained, in particular, a decrease of general toxicity of the agents, due to generally lower doses required.…”

Section: Discussionmentioning

confidence: 99%

Interaction of Functionalized Superparamagnetic Iron Oxide Nanoparticles with Brain Structures

Cengelli

Maysinger²,

Tschudi-Monnet³

et al. 2006

J Pharmacol Exp Ther

168

108

View full text Add to dashboard Cite

Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) combined with magnetic resonance imaging (MRI) are under clinical evaluation to enhance detection of neurodegenerative diseases. A major improvement would be to link therapeutic drugs to the SPIONs to achieve targeted drug delivery, either at the cell surface or intracellularly, together with active disease detection, without inducing cell reaction. Our objectives were to define the characteristics of SPIONS able to achieve cell-specific interaction with brain-derived structures. Our system consisted in an iron oxide core (9 -10 nm diameter) coated either with dextran (Sinerem and Endorem) or various functionalized polyvinyl alcohols (PVAs) (PVA-SPIONs). We investigated the cellular uptake, cytotoxicity, and interaction of these various nanoparticles with brain-derived endothelial cells, microglial cells, and differentiating three-dimensional aggregates. None of the nanoparticles coated with dextran or the various PVAs was cytotoxic or induced the production of the inflammatory mediator NO used as a reporter for cell activation. AminoPVASPIONs were taken up by isolated brain-derived endothelial and microglial cells at a much higher level than the other SPIONs, and no inflammatory activation of these cells was observed. AminoPVA-SPIONs did not invade brain cells aggregates lower than the first cell layer and did not induce inflammatory reaction in the aggregates. Fluorescent aminoPVASPIONs derivatized with a fluorescent reporter molecule and confocal microscopy demonstrated intracellular uptake by microglial cells. Fluorescent aminoPVA-SPIONs were well tolerated by mice. Therefore, functionalized aminoPVA-SPIONs represent biocompatible potential vector systems for drug delivery to the brain that may be combined with MRI detection of active lesions in neurodegenerative diseases.Nanotechnologies and nanostructures are becoming an option in human medical application, including imaging or the delivery of therapeutic drugs to cells, tissues, and organs. Most of these latter applications would require that drugloaded nanoparticles enter organ and tissues and are taken up by cells. Several studies have shown that the tissue, cell, and even cell organelle distribution (Alexiou et al., 2000;Savic et al., 2003) of drugs may be controlled and improved by their entrapment in colloidal nanomaterials, mainly of the micellar structure, such as nanocontainers. The development of a large variety of colloidal dispersions of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) has added a supplementary function to nanomaterials, their magnetic properties, which can lead to a range of new biological, biomedical, and diagnostic applications. In particular, the application of the different forms of iron oxides for radiological diagnostic procedures to document vascular leakage, macrophage imaging, or cell tracking (Weissleder et al

show abstract

Section: Discussionmentioning

confidence: 99%

Interaction of Functionalized Superparamagnetic Iron Oxide Nanoparticles with Brain Structures

Cengelli

Maysinger²,

Tschudi-Monnet³

et al. 2006

J Pharmacol Exp Ther

168

108

View full text Add to dashboard Cite

show abstract

“…10.3c) to Yoshida sarcoma tumors in a rat model, and resulted in complete remission of the disease [148]. In addition, MTC-DOX, another magnetic microparticle, proved successful in animal models; however, it failed to reach clinical trials in 2004 [149]. Studies were later refocused to involve magnetic NPs of < 10 nm diameter, as they offer superior biocompatibility, biodistribution, and deeper tumor penetration than microparticles.…”

Section: Magnetic Drug Targetingmentioning

confidence: 99%

Nanomedicine—Nanoparticles in Cancer Imaging and Therapy

Hauser-Kawaguchi

Luyt

2014

Cancer Metastasis - Biology and Treatment

View full text Add to dashboard Cite

Nanomedicine refers to the application of nanotechnology in medicine, and endeavors to diagnose, treat, and/or monitor disease on a nanoscale. Cancer nanotechnology is a quickly evolving field of interdisciplinary research that involves the biomedical application of nanoparticles, which are nanoscale devices that are able to overcome biological barriers, specifically recognize a single type of cancer cell, and accumulate preferentially in tumors. Medical applications with nanoparticles are growing, as they have the potential to offer novel methods of noninvasive cancer detection, diagnosis, and treatment. Tumor targeting ligands, such as antibodies, peptides, or small molecules, can be attached to nanoparticles for targeting of tumor antigens and vasculatures with high affinity and specificity. In addition, diagnostic agents (i.e. optical, radiolabels, or magnetic) and chemotherapeutic drugs can be integrated into their design for more efficient imaging and treatment of the tumor with fewer side effects. Recent advances in nanomedicine raise exciting possibilities for future nanoparticle applications in personalized cancer therapy.

show abstract

“…Retardation of tumor growth and even local remissions were observed [191]. A different type of magnetic particles (MTCs, magnetic targeted carriers) [192][193][194][195] are used in another clinical study with magnetically targeted doxorubicin where reportedly 32 patients have been enrolled [196]. However, in the meantime a phase II/III clinical trial involving this technology has been discontinued as the clinical endpoints could not be met with statistical significance (http://freshnews.com/news/biotech-biomedical/article 17775.html).…”

Section: Vector Localization By Magnetic Force (Magnetofection)mentioning

confidence: 99%